See today's BioWorld Science
To read the full story, subscribe or sign in.
Ear, Nose and Throat

FDA awards orphan drug designation to Sensorion's OTOF-GT for otoferlin gene-mediated hearing loss

Nov. 30, 2022
The FDA has awarded orphan drug designation to Sensorion SA's OTOF-GT, a dual vector AAV gene therapy, for the treatment of otoferlin gene-mediated hearing loss.
BioWorld Science Ear, nose and throat Gene therapy FDA Orphan drug